Co-blockade of the T-cell immunoreceptor with Ig and ITIM domains – TIGIT, for short – is being widely studied as a way of widening the pool of candidates that could benefit from checkpoint inhibition, while potentially improving the efficacy of PD-1/PD-L1 monotherapy. However, initial enthusiasm that this strategy could prove fruitful has been subdued after disappointing findings released in 2022.
After the rampant success of PD-1/PD-L1-targeted drugs such as Keytruda, Opdivo, and Tecentriq – checkpoint inhibitor revenues hit roughly $33bn...
